Skip to main content
Year archive

argenx SE — 2023 filings

All 67 regulatory filings released by argenx SE (1AE) in 2023, sourced directly from the official regulator.

67 Filings
2023 Period
2023 filings (67)
Filing Released Lang
FORM 6-K
Foreign Filer Report
2023-12-20 English
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
Earnings Release Q4 2023
2023-12-20 English
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-12-08 English
FORM 6-K
Foreign Filer Report
2023-11-28 English
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Earnings Release Q4 2023
2023-11-28 English
FORM 6-K
Foreign Filer Report
2023-11-17 English
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
Regulatory Filings
2023-11-16 English
FORM 6-K
Foreign Filer Report
2023-11-01 English
argenx to Present at Upcoming Investor Conferences
Regulatory Filings
2023-11-01 English
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
Earnings Release Q4 2023
2023-11-01 English
FORM 6-K
Foreign Filer Report
2023-10-31 English
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
Interim / Quarterly Report Q3 2023
2023-10-31 English
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
Report Publication Announcement
2023-10-24 English
FORM S-8
Registration Form
2023-09-27 English
FORM 6-K
Foreign Filer Report
2023-09-21 English
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
Regulatory Filings
2023-09-21 English
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
Earnings Release Q3 2023
2023-09-15 English
argenx to Present at Upcoming Investor Conferences
Regulatory Filings
2023-08-30 English
6-K
Foreign Filer Report
2023-07-27 English
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
Earnings Release H1 2023
2023-07-27 English
argenx announces closing of global offering
Share Issue/Capital Change
2023-07-25 English
FORM 6-K
Foreign Filer Report
2023-07-20 English
424B5
Prospectus
2023-07-20 English
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
Report Publication Announcement
2023-07-20 English
argenx announces full exercise of underwriters’ option to purchase additional ADSs
Share Issue/Capital Change
2023-07-20 English
argenx raises $1.1 billion in gross proceeds in a global offering
Share Issue/Capital Change
2023-07-19 English
argenx announces launch of proposed global offering
Capital/Financing Update
2023-07-18 English
424B5
Prospectus
2023-07-17 English
FORM 6-K
Foreign Filer Report
2023-07-17 English
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Regulatory Filings
2023-07-17 English
FORM 6-K
Foreign Filer Report
2023-06-30 English
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Regulatory Filings
2023-06-30 English
FORM 6-K
Foreign Filer Report
2023-06-21 English
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
Regulatory Filings
2023-06-21 English
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Regulatory Filings
2023-06-20 English
argenx to Present at Upcoming Investor Conferences
Report Publication Announcement
2023-05-31 English
FORM 6-K
Foreign Filer Report
2023-05-05 English
FORM 6-K
Foreign Filer Report
2023-05-05 English
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
Interim / Quarterly Report Q1 2023
2023-05-04 English
argenx announces results of Annual General Meeting of Shareholders
AGM Information
2023-05-04 English
argenx to Present at BofA Securities 2023 Health Care Conference
Report Publication Announcement
2023-05-02 English
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
Earnings Release Q1 2023
2023-04-27 English
FORM 6-K
Foreign Filer Report
2023-04-18 English
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
Regulatory Filings
2023-04-18 English
FORM 6-K
Foreign Filer Report
2023-04-17 English
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Regulatory Filings
2023-04-17 English
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
AGM Information
2023-03-20 English
20-F
Annual Report FY 2022
2023-03-16 English
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-03-16 English
FORM 6-K
Foreign Filer Report
2023-03-16 English
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
Regulatory Filings
2023-03-15 English
FORM 6-K
Foreign Filer Report
2023-03-02 English
argenx Announces Planned Transition of Chief Operating Officer
Board/Management Information
2023-03-02 English
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
Earnings Release FY 2022
2023-03-02 English
argenx Appoints Steve Krognes to Board of Directors
Board/Management Information
2023-02-28 English
argenx to Present at Upcoming Investor Conferences
Investor Presentation
2023-02-27 English
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
Report Publication Announcement
2023-02-23 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English
SC 13G/A
Major Shareholding Notification
2023-02-10 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-01 English
FORM 6-K
Foreign Filer Report
2023-01-30 English
FORM 6-K
Foreign Filer Report
2023-01-27 English
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
Regulatory Filings
2023-01-27 English
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
AGM Information
2023-01-17 English
FORM 6-K
Foreign Filer Report
2023-01-09 English
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
Earnings Release FY 2022
2023-01-09 English